CAT discloses Humira royalty issues

Cambridge Antibody Technology (LSE:CAT; CATG) and Abbott (ABT) are planning to hold talks related to the royalty rate that CAT will receive on sales of ABT's Humira adalimumab ( D2E7) rheumatoid arthritis drug. The companies' dispute concerns whether ABT can deduct royalties owed to third parties from royalties owed to CAT. CAT said it believes this is not permitted under the companies' 1995 deal, but noted that "this view has not been confirmed by Abbott." The first royalty payment due to CAT is in October. ...